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Background: Mutations in the gene encoding thymidine kinase 2 (TK2) result in the myopathic form of
mitochondrial DNA depletion syndrome which is a mitochondrial encephalomyopathy presenting in children.
In order to unveil some of the mechanisms involved in this pathology and to identify potential biomarkers and
therapeutic targets we have investigated the gene expression profile of human skeletal muscle deficient for TK2
using cDNA microarrays.
Results: We have analysed the whole transcriptome of skeletal muscle from patients with TK2 mutations and
compared it to normal muscle and to muscle from patients with other mitochondrial myopathies. We have
identified a set of over 700 genes which are differentially expressed in TK2 deficient muscle. Bioinformatics analysis
reveals important changes in muscle metabolism, in particular, in glucose and glycogen utilisation, and activation of
the starvation response which affects aminoacid and lipid metabolism. We have identified those transcriptional
regulators which are likely to be responsible for the observed changes in gene expression.
Conclusion: Our data point towards the tumor suppressor p53 as the regulator at the centre of a network of genes
which are responsible for a coordinated response to TK2 mutations which involves inflammation, activation of
muscle cell death by apoptosis and induction of growth and differentiation factor 15 (GDF-15) in muscle and
serum. We propose that GDF-15 may represent a potential novel biomarker for mitochondrial dysfunction although
further studies are required.
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Mitochondrial myopathy and mitochondrial encephalo-
myopathy are terms that define a group of neurological
disorders characterized by defective oxidative phosphor-
ylation [1-3]. Multiple organs may be affected including
skeletal muscle, liver and central nervous system. The
genetics and pathogenesis of mitochondrial disorders are
complex because of the interaction of the mtDNA and
nuclear genomes. The mtDNA contains 37 genes encod-
ing 13 mitochondrial proteins. The remaining of the
over 1500 predicted mitochondrial proteins are encoded
by the nuclear genome [4]. The majority of these nuclear
genes are unknown (over 50 are known as disease causa-
tive genesmaking it very difficult to diagnose at the mo-
lecular level mitochondrial disorders not due to mtDNA
mutations [5,6].
Mitochondrial DNA depletion syndrome (MDS) is a clin-
ically and genetically heterogeneous subgroup of mitochon-
drial diseases of nuclear origin which is characterised by
severe reduction of mtDNA content in specific tissues,
mainly muscle, liver and brain To date 9 nuclear genes have
been identified as causing MDS which encode proteins
directly involved in the maintenance of the mitochon-
drial deoxyribonucleoside triphosphate pools (dNTPs)
such as Thymidine kinase 2 (TK2), deoxyguanosine kin-
ase (DGOUK), p53 dependent ribonucleotide reductase
subunit 2 (RRM2B) and thymidine phosphorylase (TYMP),
or in mtDNA replication such as mtDNA polymerase γ
(POLG) and Twinkle (C10orf2). The role of the other three
MDS causative gene products (MPV17), and the α and β
subunits of succinate-CoA ligase (SUCLG1 and SUCLA2
respectively) in mtDNA maintenance is less clear [7].
Clinically, MDS are divided into myopathic, hepatocer-
ebellar or encephalomyopathic, depending on which tis-
sues are mainly affected at the onset of the symptoms.
The myopathic form is most frequently associated with
mutations in the TK2, SUCLA2 and RRM2B genes. Thy-
midine kinase 2 is responsible for the phosphorylation of
pyrimidine nucleosides (deoxythymidine, deoxycytosine
and deoxyuridine) inside the mitochondria as part of the
salvage pathway. In contrast, thymidine kinase 1 (TK1)
participates in the de novo deoxythymidine monopho-
sphate (dTMP) synthesis pathway in the cytoplasm which
is then imported into mitochondria. In most reported
cases mutations in TK2 result in almost complete absence
of enzyme activity and as a consequence in a very severe
reduction in mtDNA content (>90%) which leads to com-
bined respiratory chain complexes deficiency. Myopathic
MDS due to TK2 defects is characterised by neonatal or
early onset of hypotonia which progresses rapidly into a
severe myopathy and infantile death because of respiratory
failure although there are reports of patients which sur-
vive longer [8,9]. Electromyography shows myopathic
signs; creatine kinase levels (CK) are markedly elevatedand lactate is moderately high. In addition to muscle
symptoms patients may also have CNS involvement
[7,10-12]. At the pathological level, muscle biopsies fre-
quently show dystrophic changes with loss of muscle fi-
bres, proliferation of connective and adipose tissues,
ragged red fibers with mitochondria proliferation and pro-
found cytochrome c oxidase deficiency and increased
intracellular lipid content [10]. To date, more than 20 mis-
sense mutations, deletions and insertions have been re-
ported in the TK2 gene. Some of them have been reported
in more than one non-related families [11,12].
Two mouse models of TK2 defects have been gener-
ated. Tk2 knocked-out mice [13,14] suffer growth re-
tardation and hypothermia and die within 2–4 weeks of
life. They show progressive depletion of mtDNA in skel-
etal muscle, heart and liver. The morphology of skeletal
muscle seems unaffected whereas cardiac muscle is dis-
organised and contains abnormally structured mitochon-
dria. The authors conclude that Tk2 is necessary for
deoxythymidine triphosphate (dTTP) synthesis in non-
replicating cells, whereas fast-replicating cells rely more
heavily on the de novo synthesis pathway. Thus, as tis-
sues mature, mtDNA replication is increasingly affected
and mtDNA depletion worsens. Detailed analysis of the
neurological features of these mice revealed an ataxic
phenotype with progressive loss of mtDNA content, re-
spiratory chain activity and protein content of mito-
chondrially encoded respiratory chain subunits in brain
tissue, which is accompanied by selective loss of neur-
onal types [13]. The Tk2 knock-in mice bear the human
H126N missense mutation and also showed growth re-
tardation and had a generalized weakness, tremor and
impaired gait [15]. Tk2 activity was severely reduced in
all tissues tested (3% and 1.7% of normal in skeletal
muscle and brain respectively) confirming that the mu-
tation severely disrupts Tk2 function. Brain and spinal
cord showed the most prominent mtDNA depletion
followed by skeletal muscle, heart and kidney whereas in
contrast to the KO model, liver mtDNA content was
normal. Activities of the respiratory chain enzymes were
selectively reduced in brain and spinal cord whereas they
were normal in skeletal muscle. Histological analysis of
skeletal muscle was unremarkable. In contrast, the
equivalent homozygous mutation in humans resulted in
severe myopathy [16]. Thus, neither of the two mouse
models replicates the severe muscle phenotype and path-
ology seen in humans.
How the muscle cell responds to mtDNA depletion,
impaired oxidative phosphorylation and severe loss of
energy production and how these mechanisms differ be-
tween MDS and other mitochondrial myopathies is not
well understood. A patient was described which survived
into adulthood. Analysis of his two consecutive muscle
biopsies revealed an increase in mtDNA content with
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crease in complex IV activity and severe muscle mass
and fibre loss [8,17]. These findings suggest that there
may have been a selective loss of the most affected fibres
and that a compensatory mechanism may be acting in
these patients to maintain mtDNA levels in surviving
muscle fibres. Identification of such compensatory path-
ways would be of great importance to devise potential
therapies.
In order to address some of these questions we under-
took global gene expression analysis of muscle biopsies
from MDS patients with mutations in TK2 and compared
it with that of patients with mtDNA large deletions and
aged matched normal muscle. We found a large number
of genes whose expression was significantly changed
which represent the molecular signature of TK2 deficient
human muscle. Our data show that the activation of p53
signalling pathway is relevant to the pathogenesis of TK2
defects and show that energy production via glucose and
glycogen metabolism are significantly impaired at the
transcriptional level. In contrast, genes known to be part
of the starvation response mechanism were increased. We
describe the over-expression of growth and differentiation
factor 15 (GDF-15) in muscle and serum and its potential
use as a novel biomarker of mitochondrial disease.
Results
Patients and microarray
In the cDNA microarray we included 4 unrelated pa-
tients with MDS and mutations in TK2 (patients 1, 2, 3
and 4, MDS group), 4 patients with large mtDNA dele-
tions as disease control group (patients 5, 6, 7 and 8,
MDEL group) and 4 aged-matched healthy individuals
(normal control group) (Table 1). Whole genome was
analysed using Agilent Human 8 × 60K arrays. Standard
array quality controls were performed showing satisfac-
tory results. Unsupervised bi-clustering analysis consider-
ing the Agilent oligonucleotides with the largest variations
across the whole experiment showed an appropriate seg-
regation of the different samples. Data has been deposited
at the National Centre for Biotechnology Information
Gene Expression Omnibus (GEO) database as GEO Series
accession number GSE43698.
Genes differentially expressed in mtDNA depleted muscle
versus control muscle
Summary
Using the statistical test RankProd we identified 336
unique genes that were significantly under-expressed and
437 that were significantly over-expressed at FDR < 0.05 in
MDS muscle compared to control muscle (Table 2). The
list of differentially expressed unique genes is shown in
Additional file 1. The 10 top under-expressed and over-
expressed genes in this comparison are listed in Table 3.The fold changes are remarkable, particularly for the in-
duced genes (up to 188 fold increase) whereas they are
more moderate for the repressed genes (maximum 10 fold
decrease).
Amongst the top under-expressed genes we found
some genes encoding skeletal muscle components
characteristic of type II muscle fibres (fast) such as
sarcoplasmic reticulum Ca2+ ATPase 1 (ATP2A1), myosin-
light chain kinase 2 (MYLK2), actinin-type 3 (ACTN3)
and aquaporin-4 (AQP4). These changes indicate a se-
lective loss of type II fibres. In fact, type 1 predominance
has been reported in some of the patients included in
our microarray [11,12].
Fructose-1,6-bisphosphatase 2 (FBP2) is the gene en-
coding the muscle specific enzyme responsible for the
hydrolysis of fructose-1, 6-bisphosphatase into fructose
6-phosphate and inorganic phosphate during gluconeo-
genesis. As we will see later we found several other genes
involved in glucose and glycogen metabolism amongst the
significantly under-expressed genes including glycogen
phosphorylase (PYGM).
Ankyrin repeat domain-containing protein 23 is a mem-
ber of the muscle ankyrin repeat protein family (MARP).
The protein is localized to the nucleus, functioning as a
transcriptional regulator. Expression of this protein is in-
duced during recovery following starvation [18].
Glutamate-ammonia ligase (or gluthamine synthethase,
GLUL) is responsible for the synthesis of glutamine. GLUL
is expressed throughout the body and plays an important
role in controlling body pH and removing ammonia from
the circulation [19].
The ARRDC2 protein belongs to a family of proteins
some of which are involved in ubiquitination by the E3
NEDD4 ligase [20,21]. TRIM63 encodes for the muscle
specific E3 ubiquitin ligase MURF1 which is involved in
regulating skeletal muscle fibre atrophy. We and others
have found decreased TRIM63 RNA expression in chronic
atrophy and in diseased muscle [21].
Regarding the top over-expressed genes, growth and
differentiation factor 15 (GDF-15) encodes a cytokine
which has been involved in a variety of processes includ-
ing reduced risk of miscarriage and myocardial infarc-
tion [22]. Tribbles-homolog 3 (TRIB3) is a pseudokinase
which negatively regulates NF-κB signalling and sensi-
tizes cells to TNF and TRAIL induced apoptosis. In
addition, expression of TRIB3 increases during periods
of reduced nutrient supply to induce lipolysis [23].
MYH3, MYH8 and TNNT2 encode for the neonatal,
embryonic myosin heavy chain and cardiac troponin 2 re-
spectively and are markers of muscle fibre regeneration.
COL19A1 encodes for the alpha-1 chain of collagen
XIX which we have found similarly over-expressed in
various dystrophies including Duchenne muscular dys-
trophy (unpublished observation) and probably reflects
Table 1 Clinical summary of patients (* indicates those patients included in the microarray analysis)
Patient Onset Main clinical symptoms Age at
biopsy
Genetics Respiratory chain
enzymes activities
Muscle
pathology
References
*P1 2 y Hypotonia, weakness, progressive gait
impairment. Unable to stand. CK 2200U/L
2 y 96% mtDNA
depletion Hom
A181V TK2
N/A Dystrophic, severe
COX reduction. No
RRF. Type 1
predominance
Family 1 P2
Galbiati et al.,
2006 [12]
*P2 3 y Hypotonia, weakness, walking difficulties,
exercise intolerance, ptosis,
ophthalmoplegia, cerebellar vermis
atrophy. CK 523U/L
4 y 92% mtDNA
depletion het
C108W + L257P TK2
Complex I, III and
IV deficiency
Dystrophic, COX
negative fibres
(74%). RRF (68%).
Moderate increase
intracellular lipid.
Type 1
predominance
Family 2 P2
Galbiati et al.,
2006 [12]
*P3 2 y Unstable gait, muscle hypotrophy.
CK 800 U/L
2 y 90% mtDNA
depletion, Hom
A181V TK2
Complex I, III, IV
and V deficiency
Dystrophic, COX
negative fibres.
Increased
intracellular lipids
Pat E Spinazzola
et al., 2009 [11]
*P4 2 y Unstable gait, muscle hypotrophy.
CK 1000U/L
2 y 90% mtDNA
depletion, Hom
A181V TK2
Complex I, III, IV
and V deficiency
Dystrophic, COX
negative fibres.
Increased
intracellular lipids
Pat C Spinazzola
et al. 2009 [11]
*P5 5 y Low stature, lactic acidosis
hypothyroidism, retinitis pigmentosa.
6 y 6331-13994 (7.7 kb)
64% mtDNA
Normal RRF
*P6 7 y Retinitis pigmentosa
leukoenchephalopathy deafness
9 y 11033-15157 70% CI-CIII/CIII RRF Pineda et al.,
2006
*P7 30 y Retinitis pigmentosa deafness, ataxia,
myopathy, heart conduction defects.
30 y 6331-13994 77%
mtDNA molecules
Normal RRF
*P8 15 y PEO, pigmentary degeneration of retina,
complete AV block and myopathy
31 y 8.4 kDa deletion;
35% mtDNA
molecules
N/A COX negative
fibres and RRF.
P9 30 y Eyelid ptosis 38 y 4.8 kDa mtDNA
deletion; 40%
molecules
N/A COX negative
fibres and RRF.
P10 4 m Delayed motor milestones, hypotonia,
dystonia, severe axial muscle weakness,
brisk deep tendon reflex and mild
spasticity in lower limbs. Neurosensorial
deafness. Mild methyl malonic aciduria
7 m 87% mtDNA
depletion het. p.
G350S + p.G350V
SUCLA 2
Complex II, III and
IV deficiency
Generalized COX
reduction. No RRF.
Moderate increase
intracellular lipids
P11 1.5 y Proximal muscle weakness, mildly
elevated CK levels.
4 and
5 y
95% mtDNA
depletion het. p.
T77M + p. R161K
TK2
Normal COX negative
fibres. Type 1
predominance
Wang et al.,
2005; Vilá et al.,
2008 [8] and
2010
P12 10 yrs Exercise intolerance, myalgia, lactic
acidosis, eyelid ptosis, CK 400U/L,
hypertrophic cardiomyopathy, epilepsy
13 y A3243G tRNA-LEU
mtDNA
N/A RRF
Yrs: years; mtDNA: mitochondrial DNA; COX: cytochrome oxidase; RRF: Ragged-red-fibres; CK: serum creatine kinase; PEO: progressive external ophthalmoplegia;
CK: creatine kinase; y: years; m: months.
Table 2 Summary of differential genes in MDS vs
control muscle
MDS vs Control DOWN UP
FDR < 0.05 336 437
FDR < 0.05 & IPA SKM 268 279
Number of unique genes. MDS: mitochondrial DNA depletion syndrome
group. FDR: False Discovery Rate. IPA SKM: genes filtered by expression in
skeletal muscle according to Ingenuity Pathway Analysis database.
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of these patients [11,12].
Skeletal muscle expression
To ascertain which differentially expressed genes are
known to be expressed in skeletal muscle we filtered the
gene dataset (FDR < 0.05) using Ingenuity Pathways (IPA)-
knowledge base (which is based on GNF body atlas and
literature findings). Among the 336 under-expressed genes,
268 passed this filter and 279 among the 437 over-
expressed genes (Table 2). Using this filter we lost 2
Table 3 Top Ten under-expressed and over-expressed
genes in MDS vs control muscle
Gene name Description FC FDR
Under-expressed
ATP2A1 ATPase, Ca++ transporting, cardiac
muscle, fast twitch 1
−9.1 0
FBP2 Fructose-1,6-bisphosphatase 2 −9.1 0
MYLK2 Myosin light chain kinase 2 −7.1 0
ANKRD23 Ankyrin- repeat domain containing
protein 23
−7.1 0
ACTN3 Actinin, alpha 3 −6.9 0
AQP4 Aquaporin 4 −6.2 5.88E-04
GLUL Glutamine synthase −5.9 0.002
SMTNL2 Smoothelin-like 2 −6.2 2.86E-04
ARRDC2 Arrestin domain containing 2 −5.8 2.86E-04
TRIM63 Tripartite motif containing 63, E3
ubiquitin protein ligase
−5.5 0.002
PYGM Glycogen phosphorylase −4.8 0.001
Over-expressed
GDF15 Growth Differentiation Factor 15 188 0
MYH8 Myosin Heavy Chain Embryonic 119 0
TRIB3 Tribbles homolog 3 47 0
MYH3 Myosin Heavy Chain Neonatal 24 0
SNAR-A3 Small nuclear ILF3/NF90-associated
RNA A3
23 0
TNNT2 Troponin T2, cardiac 21 0
DEFB1 Defensin beta-1 malignant brain
tumours 1
16 0
TMEM63C Transmembrane protein 63C 16 0
DMBT1 Deleted in malignant brain tumors 1 11.3 0
COL19A1 Collagen type XIX 11 0
MDS: mitochondrial DNA depletion syndrome group. FC: fold-change; FDR:
false discovery rate.
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TMEM63C). All the top 10 under-expressed genes in
the whole set of genes passed the IPA filter. Thus, there
was very good agreement between the results of the
analysis for the whole set of genes and for the skeletal
muscle filtered one. However, IPA may discard some
genes with low basal expression levels in skeletal muscle,
genes that are tightly developmentally regulated or have
not been described as expressed in skeletal muscle. For
this reason we decided to focus on the whole set of genes
in order to avoid loosing valuable data.
Gene ontology
In order to obtain Gene Ontology enrichment analysis,
the lists of differentially over and underexpressed genes
(FDR < 0.05) were considered in the tool DAVID [24].
Those GO_BP terms (Gene Ontology Biological Process)
with a%FDR < 20 were considered as significantly enrichedand selected for further analysis (49GO_BPs for the over-
expressed genes and 91 for the under-expressed genes,
Additional file 2). For simplicity, we grouped the various
GO terms in broader GO_BP categories as shown in
Figure 1 (Additional file 2). The GO_BP classes corre-
sponding to the under-expressed genes (Figure 1A) were
mainly related to carbohydrate metabolism, respiratory
chain and oxidative phosphorylation, nucleotide metabol-
ism and muscle contraction whereas over-expressed genes
were mainly associated with inflammation, apoptosis, ami-
noacid and nitrogen compound metabolism, organic acid
synthesis, adhesion, ion homeostasis, muscle system and
oxygen transport (Figure 1B).
The inflammation gene class included components of
the complement cascade such as C3 (FC + 2.5), Major
Histocompatibility Complex Class I such as HLA-B (FC +
2.53), major Histocompatibility Complex Class II such as
HLA-DPA1 (FC + 1.7×), interleukins (IL17B, FC + 2.4)
and interferon-induced genes (IFI44, FC + 3.2 and
IFI44L, FC + 3.7). We confirmed the induction of an im-
mune response by immunohistochemistry using anti-
bodies against HLA antigen (MHC-Class I) and against
inflammatory cell markers in muscle biopsies from pa-
tients with TK2 mutations (P4 and in two consecutive bi-
opsies from an additional patient not included in the
array, P11 Table 1), a patient with MDS due to SUCLA2
mutations (P10, Table 1) and in disease controls (P5, P6
and P7 with large mtDNA deletions, Table 1). In TK2 defi-
cient muscle HLA I was expressed in the sarcolemma
and/or cytoplasm of some muscle fibres and in inflamma-
tory cells. HLA I was detected on the sarcolemma of most
fibres and in inflammatory cells in SUCLA2 deficient
muscle. In muscle from patients with large mtDNA dele-
tions, HLA I was expressed on isolated muscle fibres lo-
cated near ragged red fibres (Figure 2). In all cases, the
inflammatory infiltrate was mainly composed of macro-
phages which express CD68 (data not shown).
Within the enriched ontologies related to the regulation
of cell death by apoptosis and the cell cycle we found nu-
merous genes that were induced at comparable levels sug-
gesting their coordinated regulation. They include genes
that encode molecules that transmit apoptotic signals from
the cell surface (BID, + FC 3.2) and others that are acti-
vated via intracellular signals such as DNA damage via the
p53 pathway (osteopontin/SPP1, FC + 3.4; PUMA FC +
3.4) and genes that encode key regulators of the cell cycle
such as p21 or cyclin dependent kinase inhibitor 1
(CDKN1A, FC + 3.7) and growth arrest and DNA-damage-
inducible alpha (GADD45A FC + 2.2).
One of the most over-expressed genes in TK2 deficient
muscle corresponds to TRIB3 (FC + 47) which encodes a
putative kinase which is induced by NFκB and which in
turn inhibits the activity of the latter. TRIB3 sensitizes
cells to apoptosis induced by TRAIL and TNF and it has
Figure 1 Pie charts representing GO BP categories for (A) under-expressed and (B) over-expressed genes in MDS compared to
control muscle.
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survival effect.
Several of the apoptotic signals above mentioned con-
verge in the mitochondria and lead to the release of
cytochrome c and the activation of Apaf-1 and Caspase-3.
We investigated caspase-3 activation at the protein
level by immunofluorescence in the muscle biopsies
of 3 patients with TK2 mutations (P3, P4 and P11) and
other mitochondrial encephalomyopathies (P7 and P12,
Table 1). As a positive control we stained frozen sec-
tions from Wilms Tumor, which is a form of paediatric
nephroblastoma which shows high numbers of apop-
totic cells. We observed very strong immunoreactivity
against active caspase-3 in the cytoplasm of numerous fi-
bres in TK2 deficient muscle as well as in RRF in P7 and
P12 (Figure 3).Caspase-3 activation leads to DNA fragmentation so
we performed the TUNEL assay in muscle biopsies from
patients with TK2 mutations (P3, P4), a patient with
SUCLA2 mutations (P10, Table 1) and patients with con-
firmed mitochondrial encephalomyopathy (P6, P7 and
P12). We observed TUNEL positivity in myonuclei and
apoptotic bodies in TK2 deficient muscle as well as in
some of the myonuclei of the RRF in a patient with a
MELAS phenotype (P12) (Figure 4).
Several genes encoding enzymes involved in ami-
noacid, urea cycle and lipid metabolism were over-
expressed in response to TK2 deficiency. Noteworthy
is the induction of SHMT2 (FC + 3.4) encoding serine
hydroxymethyltransferase-2 that catalyses the conve-
rsion of serine and tetrahydrofolate (THF) to glycine
and methylene THF. More importantly in the context
Figure 2 MHC Class I antigen (HLA) expression in (A) normal muscle , (B) muscle from patient with mutations in TK2 (P4) (C) SUCLA2
(P10) and (D) in muscle bearing a large mtDNA deletion (P7). Scale bar = 25 μm.
Figure 3 TUNEL assay in sections from (A) Wilms tumor and muscle from (B) P7, (C,D) (P7) patients 3 and 4 with mutations in TK2.
Scale bar = 25 μm.
Kalko et al. BMC Genomics 2014, 15:91 Page 7 of 22
http://www.biomedcentral.com/1471-2164/15/91
Figure 4 Caspase-3 activity. (A) P5 with a large mtDNA deletion, (B) P4 and (C,D) two consecutive biopsies of P11. Scale bar = 25 μm.
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enzymes (together with thymidylate synthase (TYMS) and
dihydrofolate reductase (DHFR) involved in de novo thy-
midylate biosynthesis pathway in mitochondria [25]. Thus,
the upregulation of this pathway is likely to represent a
mechanism to compensate for the lack of dTMP as a re-
sult of the severely reduced TK2 activity in these patients.
TYMS gene expression was also increased by 1.5 fold but
DHFR was not significantly changed.
The ASS1 gene (FC + 4.7) encodes argininosuccinate
synthetase-1, a cytosolic urea cycle enzyme expressed in
most tissues. The enzyme is involved in the synthesis of
arginine and catalyses that condensation of citrulline
and aspartate to argininosuccinate using ATP. It is a key
enzyme because it links the Krebs cycle with the urea
cycle and pyrimidine synthetic pathway. Mutations in
ASS1 cause citrullinemia type I [26]. Its induction sug-
gests an increase in the rate of ammonia detoxification
and aminoacid degradation as a source of energy. Within
this category we also found ASNS (FC + 7.9) encoding
asparagine synthethase and PSAT1 (FC + 4.4) encoding
phosphoserine aminotransferase that are enzymes of the
asparagine and serine biosynthetic pathways respectively.
There was an important induction of the HMGCS2
gene (FC + 6.2) which encodes HMG-CoA synthase, as a
key enzyme in ketogenesis which is a pathway to derive
energy from fatty acids when blood glucose levels are
low or the TCA cycle is impaired. HMGCS2 has been
shown to be expressed in skeletal muscle [27] althoughketogenesis only occurs in liver cells. Thus, the signifi-
cance of HMGCS2 over-expression is unclear unless it is
related to another yet unknown function. TRIB3 (PC +
47) and FGF-21 (FC + 10) are genes involved in the
regulation of lipolysis upon nutrient deprivation [23].
Within the enriched GO_BPs related to glucose and
glycogen metabolism we found several genes encoding
for key enzymes indicating an important and coordi-
nated attenuation of those pathways at least at the gene
expression level. These included lactate dehydrogenase
A (LDHA, FC −4) and Phosphofructokinase-fructose-
biphosphatase −1 and −3 (PFKFB1, FC −3.8; PFKFB3,
FC −4.6). The two latter are enzymes that regulate the
levels of fructose-2,6-biphosphate which is a potent
stimulator of glycolysis and an inhibitor of gluconeo-
genesis. Thus, the activity of these enzymes regulates
glucose metabolism. PFKFB1 is ubiquitously expressed
whereas PFKFB3 is mainly expressed in skeletal muscle
and central nervous system. It is however worth bearing
in mind that gluconeogenesis takes places mainly in liver
whereas it is very little active in skeletal muscle and there-
fore the biochemical significance of some of the observed
changes at mRNA level remain unclear. PHKA1 (FC −3.6)
and PHKG1 (FC −3.4) encode two out of the 16 subunits
of the phosphorylase b kinase enzyme which together with
glycogen phosphorylase (PYGM, FC −4.8) regulates the
degradation of glycogen to release glucose molecules.
Amongst the under-expressed components of the mito-
chondrial respiratory chain and related genes we found
Table 4 KEGG Pathway Enrichment Analysis for
differential genes in MDS vs control muscle
KEGG Pathway FDR (%)
Over-expressed
Intestinal immune network for IgA production 0.03
Systemic lupus erythematosus 0.05
Viral myocarditis 0.09
Type I diabetes mellitus 0.10
Allograft rejection 0.33
Graft-versus-host disease 0.52
Cell adhesion molecules (CAMs) 0.67
Asthma 0.92
p53 signaling pathway 2.05
Autoimmune thyroid disease 2.20
PPAR signaling pathway 2.24
Glycine, serine and threonine metabolism 8.98
Under-expressed
Cardiac muscle contraction 1.16E-04
Glycolysis/gluconeogenesis 0.05
Fructose and mannose metabolism 0.09
Hypertrophic cardiomyopathy (HCM) 0.61
Dilated cardiomyopathy 1
Calcium signaling pathway 1.9
Starch and sucrose metabolism 2.4
Arrhythmogenic right ventricular cardiomyopathy (ARVC) 7.2
MDS: mitochondrial DNA depletion syndrome group. FDR: false discovery rate.
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cytochrome c subunit II (COX 2, FC −3.7) and aarF do-
main containing kinase 3 (ADCK3, FC − 3.4) which is in-
volved in the synthesis of Coenzyme Q.
Regarding genes involved in nucleotide metabolism that
were under-expressed it is worth mentioning guanosine
monophosphate reductase (GMPR1, FC −3.3) which cata-
lyses the irreversible NADPH-dependent reductive de-
amination of guanosine monophosphate (GMP) to inosine
monophosphate (IMP) which is the precursor of both
guanine (G) and adenine (A) nucleotides. Thus, it plays an
important role in maintaining the intracellular balance of
purine nucleotides.
Within the calcium/ion transport gene category of
under-expressed genes we found calcium channels such
as plasma membrane calcium-transporting ATPase 2
(ATP2B2, FC −3.2), calcium channel, voltage-dependent,
L type, alpha 1S subunit, (CACNA1S, FC −3.6), potas-
sium channels such as ATP-sensitive inward rectifier potas-
sium channel 12 (KCNJ12, FC −4) and sodium channels
including Sodium channel voltage gated Type 1, beta sub-
unit (SCN1B, FC −5.3) which is the channel that serves to
transmit membrane action potentials in the CNS and skel-
etal muscle and is localised both in plasma membrane or in
the mitochondrial membrane.
KEGG pathway analysis
The DAVID functional analysis tool was used for the
KEGG canonical pathways enrichment analysis using
the list of differentially expressed transcripts (FDR <
0.05, Table 2). Pathways terms with a% FDR < 20 were
considered as significantly enriched. We obtained re-
sults in agreement to the GO_BP analysis described
above (Table 4). Amongst the over-expressed genes, 12
categories were significantly over-represented (%FDR <
20), 8 were related to immune response, 1 to aminoacid
metabolism, 1 to cell adhesion, 1 to p53 signalling path-
way and 1 to PPAR signalling pathway. Within the p53-
signalling pathway KEGG identified three additional
genes which were not identified by GO: DNA damage
binding protein-2 or p48 (DDB2) which is expressed in
a p53 dependent manner and is involved in global genome
repair¸ tumor necrosis factor receptor superfamily 10B or
death receptor 5 (TNFRSF10B) which is a TRAIL receptor
which engages a caspase dependent apoptosis cascade in-
volving the intracellular adaptor FADD and is induced by
DNA damage in a p53 dependent manner and thirdly, p53
effector-related to PMP22 (PERP) which is a tumor sup-
pressor gene encoding a transmembrane protein widely
expressed in response to p53. For the under-expressed
genes, KEGG identified 7 significantly enriched path-
ways that could be grouped into those related to muscle
contraction (4), sugar and glycogen metabolism (3) and
calcium homeostasis (1). Thus, KEGG analysis reinforcedand complemented the GO data and highlighted the im-
portance of the p53 pathway.
Ingenuity pathways analysis (IPA)
We applied IPA to the list of differential genes to further
explore the biological significance of the expression data.
IPA predicts those affected molecular functions, the up-
stream regulators (transcription factors) which appear to
be activated within a set/group of differential genes as
well as the diseases and disorders which are likely to be
associated with a given expression profile (Table 5). The
top 3 molecular functions associated with TK2 defi-
ciency consisted of cell death and survival, cellular func-
tion and maintenance (related to actin cytoskeleton) and
small molecule biochemistry (removal of D-glucose).
Another function predicted to be activated was immune
cell trafficking (containing genes for cytokines and com-
plement system) whereas functions related to cardiovas-
cular and skeletal system development and function were
predicted to be diminished.
IPA allows the identification of the cascade of upstream
transcriptional regulators (TF) that can explain the ob-
served gene expression changes in a user’s dataset. It is
Table 5 Biological functions associated with TK2
deficiency according to Ingenuity Pathway Analysis
Category Function P-value molecules
Diseases and disorders
Cancer 1.88E-14 -
1.18E-02
253
Neurological
Disease
1.81E-11 -
8.60E-03
160
Skeletal and
muscular
disorders
1.81E-11 -
8.38E-03
166
Cardiovascular
disease
3.52E-09 -
1.14E-02
102
Hereditary
disorder
6.31E-08 -
1.18E-02
98
Molecular and
cellular functions
Cell death and
survival
2.63E-08 -
1.11E-02
165
Cellular function
and maintenance
1.02E-05 -
1.06E-02
135
Small molecule
biochemistry
1.02E-05 -
1.18E-02
105
Cell signaling 1.17E-05 -
1.18E-02
38
Vitamin and
mineral
metabolism
1.17E-05 -
1.18E-02
31
Physiological system
development and function
Skeletal and
muscular system
development and
function
1.22E-20 -
1.18E-02
99
Embryonic
development
1.89E-05 -
1.18E-02
82
Organ
morphology
1.22E-20 -
1.18E-02
80
Organ
development
1.89E-05 -
1.18E-02
63
Cardiovascular
system
Development
and function
1.66E-07 -
8.20E-03
57
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their targets in the Ingenuity Knowledge database. When
the direction of change is consistent with the literature (ex-
pression in the dataset relative to control) across the major-
ity of targets for a given TF then the TF is predicted to be
active. IPA identified TP53, TP63, HTT, TP73 and NCOA2
as the top 5 activated TF in our dataset (TK2 deficient
muscle versus control muscle).
TP53, TP63 and TP73 belong to the same family and
encode tumour proteins that are key regulators of cell
survival and cell death. HTT encodes for Huntingtinwhich up-regulates the expression of Brain Derived
Neurotrophic Factor (BDNF). The nuclear receptor co-
activator 2 (NCOA2) is a transcriptional coregulatory
protein that acylates histones, which makes downstream
DNA more accessible to transcription.
IPA identified several highly connected and well scored
networks of interacting genes consisting on a number of
the over-expressed and under-expressed genes identified
in our study (focus genes) and others that the software
predicts as also forming part of the same network. Highly
interconnected networks are likely to represent significant
biological function, and a score is calculated as the likeli-
hood that focus proteins are in the network due to ran-
dom chance. Of particular interest was the network “Cell
Death and Survival, DNA Replication, Recombination,
and Repair, Cellular Response to Therapeutics” network
which is shown in Figure 5. Hub genes in this network
are PUMA/BBC3, PERP, BID, TNFSF10, TNFRSF10B,
TP53I3, MX1, ISG15 as focus genes, and TP53, RELA,
MDM2, CDK2, CDK4, YY1, CASP3, CASP8 as non-
focus genes. TP53 shows the highest connectivity as
clearly revealed by the representation of the network.
The cellular sub-localisation for each node, when known,
is also given.
Genes differentially expressed in skeletal muscle with
large mtDNA deletions versus mTDNA depleted muscle
Summary
In order to discern those gene expression changes specific
to mtDNA depletion and not due to generalised mitochon-
drial dysfunction we used muscle with large mtDNA de-
letions as a disease control (MDEL) since these can also
present in children, affect several mtDNA genes and
muscle samples are more widely accessible. Using the
statistical test RankProd we identified 455 and 638
unique genes that were significantly under-expressed
or over-expressed respectively (FDR < 0.05) in MDEL
muscle relative to MDS muscle (Table 6). Thus, the expres-
sion profile of both groups of mitochondrial myopathies is
markedly different. The complete list of differentially
expressed genes between these two groups is shown in
Additional file 3.
The Top 10 under-expressed and over-expressed genes
in this comparison are listed in Table 7. The top 10
under-expressed genes coincide with genes which are
very significantly over-expressed in TK2 deficient versus
control muscle. This is the case for the markers of
muscle fibre regeneration (MYH3, MYH8 and TNNT2)
and fibrosis (COL19A1). This reflects the differences in
the pathology of both forms of mitochondrial disease,
muscle biopsies from patients with MDEL generally do
not show proliferation of connective tissue or generation
and in fact CK levels are normal whereas they are ele-
vated in MDS patients with TK2 mutations.
Figure 5 IPA graphic representation of the network “Cell death and survival, DNA replication, recombination, and repair, cellular
response to therapeutics”. Nodes represent genes and lines show the relationship between genes. The intensity of the node colour indicates
the degree of the over-expression (red) or under-expression (green) and the fold change is indicated. The cellular sub-localisation for each node,
when known, is also given.
Table 6 Summary of differential genes in MDEL vs MDS
muscle
MDEL vs MDS DOWN UP
FDR < 0.05 455 638
FDR < 0.05 & IPA SKM 352 501
Number of unique genes. MDEL: mitochondrial DNA deleted group. MDS:
mitochondrial DNA depletion syndrome group. FDR: False Discovery Rate. IPA
SKM: genes filtered by expression in skeletal muscle according to Ingenuity
Pathway Analysis.
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genes in this comparison correspond to genes which
are significantly under-expressed in TK2 deficient
muscle relative to controls such as FBP2 and ATP2A1
highlighting the marked repression of those two genes
(associated with attenuated glycolysis and loss of fast fi-
bers) in the MDS group. There are however two genes
which are significantly over-expressed in KSS relative to
MDS which are not significantly altered in TK2 defi-
cient muscle. These encode Keratin-associated-protein
Table 7 Top 10 under-expressed and over-expressed
genes in MDEL vs MDS groups
Gene Name Description FC FDR
Under-expressed
MHY3 Myosin Heavy Chain Neonatal −61.4 0
MHY8 Myosin Heavy Chain Embryonic −32.9 0
GDF15 Growth Differentiation Factor 15 −30.4 0
SNAR-A3 Small nuclear ILF3/NF90-associated
RNA A3
−15.8 0
TNNT2 Troponin T2, cardiac −15.5 0
MYBPH Myosin binding protein −14.6 0
DMBT1 Deleted in malignant brain tumors 1 −11.8 0
LMF1 Lipase maturation factor 1 −10 0
COL19A1 Collagen type XIX −9.9 0
TRIB3 Tribbles homolog 3 −9.6 0
Over-expressed
FBP2 Fructose-1,6-bisphosphatase 2 18.4 0
AQP4 Aquaporin 4 17.3 0
C8ORF22 14.2 0
ATP2A1 ATPase, Ca++ transporting, cardiac
muscle, fast twitch 1
10.8 0
KRTAP3-3 Keratin-associated-protein 3 10.6 0
C15ORF27 8 0
CALML6 Calmodulin like 6 8 0
DHRS7C Dehydrogenase/reductase (SDR family)
member 7C
7.9 0
MLF1 Myeloid leukemia factor 1 7.1 0
TSPAN8 Tetraspanin-8 7 0
MDEL: mitochondrial DNA deleted group. MDS: mitochondrial DNA depletion
syndrome group. FC: fold-change. FDR False Discovery Rate.
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protein, calmodulin-like 6 (CALML6).
Gene ontology
GO analysis revealed induction of several metabolic path-
ways (76 GO_BP categories%FDR < 20) in the MDEL
group relative to MDS muscle (Additional file 4). 53 of
those were the same GO_BPs that were repressed in MDS
muscle relative to normal muscle and were mainly related
to glucose and glycogen metabolism and skeletal muscle
system. The remaining 23 GO_BPs were unique to the
MDEL_MDS comparison. Out of those we were particu-
larly interested in the 7 categories related to protein catab-
olism, the TCA cycle (3) and co-factor metabolism (4)
Within the protein catabolism category we found 40
unique genes. These encode several ubiquitin-specific-
proteases (UPS2, USP13, USP 15, USP24, USP25, USP38,
USP47), which are responsible for the release of ubiqui-
tin from degraded proteins, genes encoding for ubiquitin-
conjugating enzymes (UBE2G1, UBE2D4, UBE2D1,UBE2B, UBE2E3), which catalyse the second step in the
ubiquitination process and several components of the
E3 ubiquitin- ligase complex (TRIM63, NEDD4, FEM1A,
CUL3, RNF123, WWP1, DCUN1D2, RNF41).
The TCA related GO functionalities contained 6 unique
genes encoding for subunits B and C of the respiratory
chain complex II (SDHB and SDHC), subunits beta of
succinate-CoA ligase (SUCLG2 and SUCLA2), Dihydroli-
poyl dehydrogenase (DLD) and isocitrate dehydrogenase
(IDH2) both of which participate in pyruvate metabolism.
The co-factor metabolism category included genes enco-
ding various enzymes and co-factors such as pantothenate
kinase 4 (PANK4) and phosphopantothenoylcysteine
decarboxylase (PPCDC), both of which participate in Co-
enzyme A biosynthesis, and COX10 which is important
for assembly of complex IV of the respiratory chain.
There were 79 GO_BP categories significantly repressed
in MDEL versus MDS group (Additional file 4). 56 of them
were not induced in MDS group relative to control.
Angiogenesis appeared to be attenuated in MDEL group
relative to MDS with 17 unique genes significantly under-
expressed including various collagen genes (COL1A1,
COL1A2, COL3A1, COL5A1, COL18A1), proteoglycans
(CSPG4), blood vessel survival factors (ANGPTL4), growth
factors (FGF9) and early response genes downstream of
growth factors such as ZFP36L1.
Thus, this GO analysis indicates that intermediate me-
tabolism involving the TCA cycle and protein breakdown
via the ubiquitin-proteasome system are significantly in-
duced as a result of large mtDNA deletions. In contrast,
angiogenesis is impaired.
KEGG pathway analysis
KEGG identified 9 canonical pathways as significantly
enriched in MDEL relative to MDS including the TCA
cycle (Table 8). Only 5 canonical pathways appeared at-
tenuated in MDEL relative to MDS amongst which we
found p53 signalling and two pathways related to the
immune response.
Meta-analysis
In order to find out how many genes were differentially
expressed in common in both the MDS and MDEL
groups, relative to normal muscle, we applied the web
based application BioVenn [28] which allows comparing
and visualising gene lists. 79 unique genes (less than 10%
of the 804 genes) were in common (both up and down),
Table 9.
These included GDF-15, haemoglobin genes (HBA2,
HBB and HBD), inflammation related genes (C3, IL17D,
IL32, DEFB1), collagens (COL1A1, COL21A1), fatty acid
transport (CD36, FABP4 and FAB5). In most cases the
direction of the change was the same (up or down) but to a
different degree. For example, in MDS muscle ACTN3 was
Table 8 KEGG Pathway Enrichment Analysis for
differential genes in MDEL vs MDS muscle
KEGG Pathway % FDR
Over-expressed
hsa04260:Cardiac muscle contraction 0.09341201
hsa04020:Calcium signaling pathway 0.162733253
hsa00010:Glycolysis / Gluconeogenesis 1.309001667
hsa00020:Citrate cycle (TCA cycle) 4.872315134
hsa00260:Glycine, serine and threonine metabolism 4.872315134
hsa05012:Parkinson’s disease 6.113594087
hsa04910:Insulin signaling pathway 8.953173862
hsa05010:Alzheimer’s disease 13.57653918
hsa00190:Oxidative phosphorylation 17.58596026
Under-expressed
hsa04512:ECM-receptor interaction 1.95E-04
hsa04115:p53 signaling pathway 0.221772048
hsa05322:Systemic lupus erythematosus 0.910185594
hsa04510:Focal adhesion 3.486083165
hsa04610:Complement and coagulation cascades 5.368404888
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under-expressed by 3 fold. However, for a few genes the
direction of the change was opposite. This is the case for
aquaporin 4 (AQP4) which was under-expressed (FC −6.2)
in MDS muscle whereas it was over-expressed in MDEL
muscle (FC + 2.8) and also for ANGPTL4, COL1A1,
C8orf22, MYH1 and IL71D (Table 8).
Validation of changes in expression
We selected some of the most significant and markedly
differential genes to measure their expression levels using
a quantitative PCR approach. The TK2 deficient group in-
cluded three of the four samples used in the array (P2, P3
and P4). The disease control MDEL group included three
of the four samples with large mitochondrial DNA dele-
tions used in the array (P5, P6 and P7) and an additional
sample (P9, Table 1). In addition we studied one patient
with mutations in SUCLA-2 (P10, Table 1). Results
were expressed relative to TATA box binding protein
(TBP) and hypoxanthine phosphoribosyltransferase 1
(HPRT1) as endogenous control genes to normalize
transcription levels amongst patients. Results were
analysed with qBaseplus software. FC above or below
1.5 were considered significant.
Differential expression was confirmed for all the se-
lected genes (Table 10) although the dynamic range of
differential gene expression was different for the two
techniques. This was particularly true for the genes with
the highest levels of over-expression, GDF-15, TRIB-3,
COL19A1 and FGF21. Most genes that were changed in
TK2 deficient muscle were also changed in the samedirection in muscle with SUCLA2 defects, for example,
the glycolytic genes FBP2, PFKFB3 and LDHA. However,
there were some differences such as cytochrome b which
was over-expressed instead of under-expressed as in
TK2 deficient muscle.
To confirm that muscle cells are able to transcribe some
of the mRNAs of interest we performed qRT-PCR using
RNA from the immortalised skeletal muscle cell line
LHCN-M2 (kind gift of W. Wright, UT Southwestern
Medical Centre, Dallas, US, [29] after differentiation for
5 days as well as from dermal fibroblast cultures. We
found that both muscle cells and fibroblast express similar
levels of GDF-15 transcript (based on mean CT values)
whereas fibroblast express higher levels of TRIB3 than
muscle cells. When compared to normal muscle tissue,
muscle cultures expressed significantly higher levels of
GDF-15 but comparable levels of TRIB3 (data not
shown). Thus, the source of GDF-15 could be the
muscle cells themselves as opposed to the fibroblasts
or other cell types present in the tissue.
Expression of GDF-15 as a possible biomarker of
mitochondrial disease
Growth and differentiation factor-15 (GDF-15), also known
as macrophage inhibitory cytokine-1 (MIC-1), is a member
of the transforming growth factor beta (TGF-β) super-
family. To evaluate the potential application of GDF15
as a biomarker for mitochondrial diseases we conducted
a small pilot study and measured its serum levels by
ELISA. In healthy children (n = 37) the mean concentra-
tion of GDF-15 was 380.5 pg/mL and the normal range
(mean ± 2 SD) between 59 and 701 pg/mL which is
comparable to what has been described in other studies
[30,31]. We studied 13 patients with molecularly con-
firmed mitochondrial myopathy and although the levels
of GDF-15 were highly variable they were on average
very significantly increased relative to the control
group (mean 3562 [SD 3973] pg/mL) (p = 1.19673E-05)
(Figure 6). The highest levels were detected in two patients
with POLG mutations (85252 pg/mL and 13215 pg/mL)
followed by P4 of this study carrying TK2 mutations
(8000 pg/mL) and a patient with lactic acidosis and epi-
lepsy bearing the mtDNA A3243G mutation (P12),
(6999 pg/mL). GDF-15 serum levels were within the nor-
mal range (mean 320 pg/mL) in 6 children with muscular
dystrophy (DMD n = 3 and Ullrich Congenital Muscular
Dystrophy n = 3).
In addition we measured GDF-15 levels in the condi-
tioned medium from cultures of LHCN-M2 myotubes
and normal dermal fibroblasts. We were able to detect
GDF-15 in both muscle and fibroblast cultures indicating
that both cell types are able to secrete it. Levels in muscle
cultures were higher than in fibroblasts (804 pg/mL and
150 pg/mL respectively).
Table 9 List of genes differentially expressed (over and under-expressed) relative to control muscle in both MDEL and
MDS muscle
Gene Name Description FC MDS FC MDEL
ACTN3 Actinin, alpha 3 −6.9 −2.7
AQP4 Aquaporin 4 −6.2 +2.8
MARCO Macrophage receptor with collagenous structure −4 −4.1
TNMD Tenomodulin −4 −4.7
C8orf22 Chromosome 8 open reading frame 22 −4 +3.6
ADAMTS8 ADAM metallopeptidase with thrombospondin type 1 motif, 8 - 3.7 −5.1
AGXT2L1 Alanine-glyoxylate aminotransferase 2-like 1 −3.5 −2.5
SLITRK4 SLIT and NTRK-like family, member 4 −3.3 −3.4
FNDC1 Fibronectin type III domain containing 1 −3.2 −2.5
SERPINA5 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5 −2.8 −2.4
GAS2L2 Growth arrest-specific 2 like 2 −2.8 −2.6
MYH1 Myosin, heavy chain 1, skeletal muscle, adult −2.7 +2.8
IL32 Interleukin 32 −2.6 −4
ITGA10 Integrin, alpha 10 −2.5 −3.3
FMOD Fibromodulin −2.3 −4
FOS FBJ murine osteosarcoma viral oncogene homolog −2.3 +2.4
IL17D Interleukin 17D −2.3 +2.6
EIF1AY Eukaryotic translation initiation factor 1A, Y-linked −2.2 −2.5
RPS4Y1 Ribosomal protein S4, Y-linked 1 −2.1 −2.7
GDF15 Growth and differentiation factor 15 +187.9 +6.2
MYH8 Myosin heavy chain embryonic +118.7 +3.6
TRIB3 Tribbles homologue 3 +47.1 +5
DEFB1 Defensin beta +16.6 +4.5
Tmem63c Transmembrane protein 63C +16.2 +2.9
SNORD3B-1 Small nucleolar RNA, C/D box 3B-1 +6.8 +3.2
SNORD15A Small nucleolar RNA, C/D box 15A +6.3 +3.7
SNORA28 Small nucleolar RNA, H/ACA box 28 +6.3 +4.9
ATF5 Activating transcription factor 5 +6.3 +2.1
HMGCS2 3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial) +6.2 +2.7
GOS2 G0/G1 switch regulatory protein +6.1 +4.8
HBA2 Hemoglobin, alpha 2 +5.9 +4.5
XIST X (inactive)-specific transcript (non-protein coding) +5.8 +4.1
HBD Hemoglobin, delta +5.8 +5.3
C3 Complement component 3 +5.6 +2.1
SNORA74A Small nucleolar RNA, H/ACA box 74A +5.6 +2.8
HBB Hemoglobin, beta +5.5 +4.9
SNORD17 Small nucleolar RNA, H/ACA box 17 +5.2 +2.5
PRODH Proline dehydrogenase (oxidase) 1 +5.2 +2.3
CD36 CD36 molecule (thrombospondin receptor) +4.7 +2.4
CES1 Carboxylesterase 1 +4.6 +2.9
SCL26A9 Solute-linked carrier 26 alpha 9 +4.4 +3.6
FABP5 Fatty acid binding protein 5 +4.4 +2.3
RNU105A RNA, U105A small nucleolar +4.3 +2.2
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Table 9 List of genes differentially expressed (over and under-expressed) relative to control muscle in both MDEL and
MDS muscle (Continued)
RN7SK RNA, 7SK small nuclear +4.3 +2.7
CIDEC Cell death-inducing DFFA-like effector c +3.9 +2.6
FABP4 Fatty acid binding protein 4 +3.9 +2.1
IGLL5 Immunoglobulin lambda-like polypeptide 5 +3.9 +3
ALAS2 Aminolevulinate, delta-, synthase 2 +3.3 +2.6
MYL10 Myosin, light chain 10, regulatory +3.2 +4
ADH1A Alcohol dehydrogenase 1A (class I), alpha polypeptide +3.1 +3.5
SCARNA5 Small Cajal body-specific RNA 5 +2.4 +2.4
SNORA81 Small nucleolar RNA, H/ACA box 81 +2.3 +2.3
KCNE1L KCNE1-like +3 +2.6
RBP4 Retinol binding protein 4 +2.9 +3
GZMH Granzyme H (cathepsin G-like 2, protein h-CCPX) +2.9 +2.3
HBG1 Hemoglobin, gamma A +2.7 +3.6
DPYSL4 Dihydropyrimidinase-like 4 +2.6 +3.1
FMO2 Flavin containing monooxygenase 2 +2.5 +2.6
C20orf26 Chromosome 20 open reading frame 26 +2.5 +3.5
HIST1H4L Histone cluster 1, H4l +2.5 +2.7
SCARNA16 Small Cajal body-specific RNA 16 +2.5 +3.9
COL21A1 Collagen, type XXI, alpha 1 +2.4 +2.7
ANGPTL4 Angiopoietin-like 4 +2.4 −3.5
RNU1-5 RNA, U1 small nuclear 5 +2.3 +3.8
COL1A1 Collagen, type I, alpha 1 +2.1 −4.2
RNU2-2 RNA, U2 small nuclear 2 +2 1.9
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High-sensitivity microarray technology provides a useful
tool to study changes in the whole transcriptome of skel-
etal muscle samples in relation to specific genetic or bio-
chemical mitochondrial defects [32]. This is the first
report of global gene expression analysis of TK2 defi-
cient human skeletal muscle. There is a previous study
of gene expression in fibroblasts from patients with TK2
or dGUOK mutations [33]. Using this approach we have
detected significant changes in a set of over 700 genes
which represents the adaptative response of skeletal
muscle cells to TK2 defects and the subsequent severe
mtDNA depletion. Furthermore, we have also identified
changes in common with another form of mitochon-
drial myopathy that also affects various mtDNA
encoded components of the respiratory chain. These
two pathologies only share a small proportion of differ-
ential genes compared with normal muscle which indi-
cates that the cell responds differently to various forms
of mitochondrial dysfunction and that the changes that
we have observed are specific to TK2 deficiency.
Our data indicate that TK2 deficiency results in im-
portant changes in genes involved mainly in metabolism,regulation of the cell cycle and mitochondrial DNA
maintenance, oxidative stress and apoptosis.
Metabolism
We found over-expression of several transcripts involved
in the starvation response. These include ASNS, PSAT1,
FGF-21 and TRIB3. These genes, which were also over-
expressed in twinkle deficient mouse skeletal muscle
[34], have in common the presence of an amino acid
response element (AAREs) in their promoter region
where transcription factors of the ATF family bind to in-
duce their expression upon limited nutrition [35]. Thus,
these results suggest that TK2 deficiency induces a
starvation-like response which alters lipid and aminoa-
cid metabolism.
Two out of the three key enzymes of the de novo thy-
midine nucleotide synthesis pathway were co-ordinately
over-expressed in the array, SHMT2 and TYMS. Coordi-
nated expression of both proteins, but not of the third
enzyme in the pathway, dihydrofolate reductase (DHFR),
has been previously reported [36]. This may represent
a compensatory mechanism for defective salvage path-
way due to the severe reduction of TK2 activity.
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crease in regenerating cycling muscle cells which rely on
de novo synthesis as opposed to non-regenerating
muscle which is considered post-mitotic and thus de-
pends mainly on the salvage pathway.
P53, mitochondrial DNA maintenance, cell cycle and
oxidative stress
TP53 gene encodes p53, a tumor suppressor gene which
is activated by several forms of cellular stress such as
DNA damage, oxidative stress, ribonucleotide depletion
and mitochondrial dysfunction as well as by other stim-
uli [37]. P53 plays a crucial role in the regulation of the
cell cycle, DNA repair and apoptosis [38]. Under condi-
tions of oxidative stress, p53 traslocates to mitochondria
where it binds the mitochondrial DNA polymerase (Pol γ)
and the mitochondrial transcription factor A (TFAM gene)
and promotes base excision repair and/or replication of
mtDNA. Treatment of cells with N-acetylcysteine (anti-oxi-
dant) prevents traslocation of p53 to mitochondria [39].
In the present study we have demonstrated activation of
several genes and pathways regulated by p53. PIG3, en-
coding TP53I3, a NADPH dependent medium chain de-
hydrogenase reductase (quinone reductase) was amongst
the over-expressed p53 targets. PIG3 expression can also
be activated by p63 and p73 (which are also predicted to
be activated in our data set) [40]. TP53I3 plays a dual role.
On the one hand as a ROS producer upon induction by
p53 to promote apoptosis and on the other hand as a
DNA breaks sensor that activates the DNA damage re-
sponse pathway (DDR pathway) after translocation to the
nucleus. In normal cells subjected to genotoxic stress, the
DDR pathway stabilises p53 which induces PIG3 tran-
scription. If the damage is not excessive PIG3 produces
certain amounts of ROS insufficient to induce the expres-
sion of other pro-apoptotic genes but also promotes DNA
repair. If the damage cannot be repaired very high levels
of PIG3 produce very high levels of ROS and finally trig-
ger apoptosis [40]. It is interesting to mention that TP53I3
gene is within a genomic region identified by Calvo et. al
as being linked to mitochondrial disease [4]. Although
mutations in TP53I3 gene have not been identified in
humans, a role for cancer predisposition of certain poly-
morphisms has been proposed.
We found over-expression of cyclin dependent kinase
inhibitor 1 (CDKN1A) and growth arrest and DNA-
damage-inducible alpha (GADD45A) both of which are
known to prevent progression of the cell cycle at the G1
and G2 level respectively and are downstream targets of
p53 [41] (Zhang and Chen 2008).
Thus, we hypothesise that mtDNA depletion leads to
p53 activation to promote mtDNA replication and repair
both via its role as a transcription factor and via its
interaction with Pol γ and mtTFA in mitochondria.On the other hand, mitochondrial dysfunction and sub-
sequent reactive oxygen species accumulation amplifies
the p53 signalling cascade which induces the expression
of pro-apoptotic factors, activation of caspase-3 and apop-
tosis in damaged cells.
The p53 pathway has been previously associated with
mitochondrial DNA depletion. On the one hand, p53
deficient mouse and human fibroblasts show reduced
mtDNA copy number [42].On the other hand, mutations
in RRM2B cause a severe subtype of MDS which mainly
affects skeletal muscle and kidney [7]. RRM2B encodes
the R2 subunit of the p53-inducible ribonucleotide reduc-
tase which converts ribonucleoside diphosphates into the
corresponding deoxyribonucleosides which is essential for
DNA repair [43]. Mutations in RRM2B null mice suffer
from renal failure, growth retardation, and early mortality
and show decreased mtDNA content in kidney, muscle
and liver [43]. In the present study we did not find in-
creased expression of RRM2B but its activation via post-
transcriptional mechanisms cannot be excluded.
Progressive muscle fibre loss is a feature of muscle bi-
opsies from patients with TK2 defects. Apoptosis has
been described in various neuromuscular conditions [44]
including some mitochondrial myopathies [45]. Mito-
chondria play a key role regulating the susceptibility of
cells to undergo apoptosis because they are involved in
oxidative stress, Ca2+ homeostasis and energy supply
and several of the pro- or anti-apoptotic factors localise
to mitochondria. In the present study we have demon-
strated for the first time evidence of over-expression of
several pro-apoptotic factors (some of which are regu-
lated by p53), caspase-3 enzymatic activation and DNA
fragmentation in human skeletal muscle deficient for
TK2. Anti-apoptotic drugs have been shown to prevent
apoptosis, ameliorate muscle histology, slow loss of
muscle fibres and increase body weight and survival in
animal models for congenital muscular dystrophy and
some of these drugs are under consideration for clinical
trials in humans [46]. In view of our results, the use of
such compounds may also be beneficial in TK2 deficient
muscle to prevent rapid muscle loss.
P53, glucose metabolism and oxidative phosphorylation
In addition to its role as “guardian” of the genome, p53 is
emerging as a key regulator of many metabolic processes
including glycolysis, oxidative phosphorylation, insulin
sensitivity and mitochondrial stability [47]. P53 induces the
expression of TP53-induced glycolysis and apoptosis regu-
lator (TIGAR) which affects FBP2 (fructose-2,6-biphos-
phatase), which was under-expressed at the RNA level in
our microarrays, and limits the activity of phosphofructoki-
nase 1 thus lowering the rate of glycolysis. In this way,
some glycolytic intermediates can be utilized in the pentose
phosphate pathway which feeds into de novo nucleotide
Table 10 Validation of microarray results with real time PCR
MDS MDEL SUCLA-2
Gene Description FC array FC Fluidigm FC array FC Fluidigm FC Fluidigm
FBP2 fructose-1,6-bisphosphatase 2 −9.1 −23.4 ns −1.18 −1.59
ATP2A1 ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 −9.1 −13.3 ns 1.07 1.31
PFKFB3 Phosphofructokinase-biphosphatase-3 −4.6 −1.7 ns −1.14 −2.32
LDHA Lactate-dehrydrogenase-A −4.1 −7.9 ns −1.67 −2.85
ADCK3 aarF-domain-containing kinase 3 −3.4 −2.7 ns −1.21 1.19
CYTB Cytochrome b −3 −7.63 ns −1.32 3.44
GDF15 Growth Differentiation Factor 15 188 845 6 154.6 2.46
TRIB3 Tribbles homolog 3 47 141.3 5 29.5 2.92
TNNT2 Troponin T2, cardiac 21 35.9 ns 7.3 6.62
COL19A1 Collagen type XIX 11 100.6 ns 19.7 1.66
FGF21 Fibroblast Growth Factor 21 10.8 1281.1 ns 286.8 -
HMGCS2 3-hydroxy-3-methylglutaryl-CoA synthase 2 6.2 9.2 2.7 4.99 66.85
PTPRF Receptor-type tyrosine-protein phosphatase F 6.1 9.6 ns 2.09 3.2
G0S2 G0/G1 switch regulatory protein 6.1 1.91 4.8 2.21 1.5
SHMT2 Serine hydroxyl-methyltransferase 2 3.4 4.8 ns 1.84 −1.06
ASS1 argininosuccinate synthase-1 4.7 3.1 ns 1.53 3.52
TP53I3 TP53 induced gene 3 3.5 2.42 ns −1.30 1.54
DPYSL4 Dihydropyrimidinase-related protein 4 2.6 5.48 3.1 1.30 -
TP53 ns 1.8 ns 1.01 1.61
PPARG Peroxisome proliferator-activated receptor gamma ns −1.02 ns −1.10 1.54
SUCLA2 succinate-CoA ligase, ADP-forming, beta subunit ns −2.28 ns −1.29 −1.35
TK2 Tymidine kinase 2 ns −1.19 ns −1.24 1.37
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Apoptosis Inducing Factor (AIF), which is essential for
complex I function [47] and of its mitochondrial homologue
AIFM2 which was over-expressed (FC + 2.6) in our microar-
rays Thus, it would seem that in the context of TK2 defi-
ciency, p53 may be inhibiting glycolysis and promote de
novo nucleotide synthesis. We cannot exclude that some
of the observed changes are associated with selective loss
of type II fibres.
GDF-15
In humans, GDF-15 is predominantly expressed in the pla-
centa, with low levels in the kidney, pancreas, and prostate.
However, its expression can be rapidly induced by cyto-
kines such as interleukin-1 and TGF-β [48]. GDF-15 has
diverse biological functions. Early studies have shown that
low serum GDF-15 levels correlate with miscarriages, indi-
cating that it might be able to suppress inflammation in
early pregnancy [49]. GDF-15 also plays an important role
in tumorigenesis and metastasis since it is dramatically in-
creased in many types of cancers [50]. The expression of
GDF-15 is strongly induced by p53 and anti-tumorigenic
agents, such as the non-steroidal anti-inflammatory drugs
[51]. Serum GDF-15 concentrations have been shown tobe also associated with the risk of acute coronary syn-
drome as well as its prognosis. GDF-15 can be produced
by cardiac myocytes in response to ischemia, nitrosative or
oxidative stress and angiotensin II [22].
GDF-15 mRNA was dramatically increased (by almost
200×) in TK2 deficient muscle and it was also elevated
in mtDNA deleted muscle (by 6 fold). We confirmed its
over-expression by qRT-PCR in muscle tissue and also
in the LHCM-N2 cell line demonstrating that skeletal
muscle cells can transcribe this gene. Using ELISA we
demonstrated that LHCN-M2 synthesise and secrete
GDF-15 to the extracellular space. Thus, GDF-15 could
be produced by muscle cells in vivo in response to oxi-
dative stress and p53 activation. However, contribution
from other cell types cannot be excluded.
We conducted a small pilot study to evaluate the poten-
tial application of GDF-15 as a biomarker of mitochondrial
disease by measuring its serum concentration by ELISA.
We established the normal range in our population of
healthy children and studied serum from patients with gen-
etically confirmed mitochondrial disease. On average, GDF-
15 levels in patients were 9 times higher than in the healthy
control group. Two patients had values that fell within the
broad normal range that we established (mean ± 2SD).
Figure 6 GDF-15 serum levels as measured by ELISA (pg/ml) in unaffected children (circles) and children with mitochondrial
myopathies (squares).
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times higher than the normal mean value and would fall
within a smaller range (mean ± SD). We also included 6
non-mitochondrial myopathies children with severe dys-
trophies whose GDF-15 values were normal. We are cur-
rently extending this study to include more patients with
mitochondrial diseases (with and without myopathy),
non-mitochondrial myoapthies and various neurome-
tabolic disorders, to correlate GDF-15 plasma levels with
other biochemical markers (in particular FGF-21, lactate,
pyruvate, lactate to pyruvate ratio and creatine kinase
values) [52] as well as with muscle histopathological
markers such as COX negative and/or ragged-red fibres.
In spite of the limited number of patients and disease
controls and the necessity for a larger study, the mRNA
and protein data strongly suggest that GDF-15 (alone or
in combination with other markers) may serve as a bio-
chemical marker to aid in the diagnosis of mitochondrial
diseases.
Conclusions
The integrated use of Gene Ontology, KEGG pathways,
IPA databases and statistical and visualization tools has
allowed us to place the differential gene expression data
obtained from the microarrays into a coherent func-
tional context. Our data suggest that mtDNA depletiondue to TK2 defects leads to activation of p53 signalling
pathway. P53 induction may represent a compensatory
mechanism to promote DNA repair and replication in
mitochondria. In addition, p53 inhibits glycolysis to pro-
mote the pentose synthetic pathway. The inability of
some muscle cells to replenish the dNTPs pools and
overcome the loss of mtDNA beyond a certain level
(despite the observed upregulation of two key enzymes
of the de novo synthesis pathway) is likely to result in
sustained ROS production by TP53I3 and activation of
other pro-oxidative and pro-apoptotic factors which lead
to the death of a proportion of muscle fibres. P53 and oxi-
dative stress probably induce the expression and secretion
of GDF-15 into the circulation. This finding may be
exploited as a tool for diagnosis of mtDNA depletion and
other mitochondrial myopathies although further studies
are required.Methods
Ethics statement
This work has been approved by the Ethical Committee
of “Fundació Sant Joan de Déu”.
Written informed consent for research was obtained
from all patients (or their parents/guardians) according
to the Hospital Sant Joan de Déu forms and regulations.
Kalko et al. BMC Genomics 2014, 15:91 Page 19 of 22
http://www.biomedcentral.com/1471-2164/15/91Muscle biopsies
Open muscle biopsies (from left quadriceps or deltoid
muscles) were performed, oriented and frozen according
to standard procedures [53]. Lower limb muscle samples
were obtained from children non-affected by a neuro-
muscular disease (control muscle group) who underwent
orthopaedic surgery at the Hospital Sant Joan de Déu.RNA preparation
Total RNA was extracted from biopsies (30 mg) or
cells with RNeasy Fibrous Tissue mini kit (Qiagen, Hilden,
Germany). Muscle tissue was homogenized with TissueRup-
tor (Qiagen, Hilden, Germany) following the manufacturer’s
instructions. Quantity and quality of RNA obtained was
determined with Nanodrop 8000 Spectrophotometer
(Thermo Scientific, Schwerte, Germany) and its integrity
with Agilent 2100 Bioanalyzer (Agilent technologies,
Waldbronn, Germany). In all samples RNA integrity num-
bers (RIN) were >7 and 260/280 ratios near 2.0. 0.15 mg
of RNA was retro-transcribed with SuperScript III First-
Strand Synthesis Super-Mix for qRT-PCR (Invitrogen™,
Carlsbad, CA, USA) to obtain cDNA and then was
amplified with Taqman PreAmp Master Mix (Applied
Biosystems, Foster City, CA, USA) following manufac-
turer’s instructions.Microarray experiments
Cyanine-3 (Cy3) labeled cRNA was prepared from 100 ng
of RNA using the LowInputQuick Amp Labeling kit
(Agilent technologies, Waldbronn, Germany) according to
the manufacturer’s instructions, followed by RNAeasy
column purification (Qiagen, Hilden, Germany). Dye
incorporation and cRNA yield were checked with the
NanoDrop ND-1000 Spectrophotometer. 600 ng of Cy3-
labelled cRNA (specific activity >10.0 pmol Cy3/ug cRNA)
was fragmented at 60°C for 30 minutes in a reaction vol-
ume of 25 ul containing 1× Agilent fragmentation buffer
and 2× Agilent blocking agent following the manufacturer’s
instructions. On completion of the fragmentation reaction,
25ul of 2× Agilent hybridization buffer was added to the
fragmentation mixture and hybridized to Agilent SurePrint
G3 Human Gene Expression 8 × 60K arrays (G4851A-
028004, Agilent technologies, Waldbronn, Germany) for
17 hours at 65°C in a rotating Agilent hybridization oven.
After hybridization, microarrays were washed 1 minute at
room temperature with GE Wash Buffer 1 and 1 minute
with37°CGEWashbuffer2(Agilenttechnologies, Waldbronn,
Germany). Scanned on an Agilent G2539A scanner at
3um resolution and 100%PMT. The intensity data of each
individual hybridization were extracted and the quality was
assessed with the Feature Extraction software 10.7 (Agilent
technologies, Waldbronn, Germany). Raw data was cor-
rected for background noise using the Normexp method.Quantile normalization method was applied to assure com-
parability across samples [54].
Microarray statistical analysis
Statistical differential gene expression analysis between
groups was performed by the non-parametric approach
Rank Prod [55] which detects genes that are consistently
highly ranked in a number of replicate experiments, a
method that has shown robustness to outliers and being
particularly powerful when small number of replicates is
available. Those oligonucleotides that present changes be-
tween groups with FDR (false discovery rate) value lower
than 0.05 were considered significant. The tool DAVID
[24] was used for the calculation of the functional over-
representation statistics of the different lists of significant
genes obtained with Rank Prod analysis. Gene Ontology
Biological Process and KEGG pathways data bases (Kyoto
Encyclopedia of Genes and Genomes, Kanehisa, Goto
et al., 2002) were considered. Also, interaction networks
have been constructed using the Ingenuity Pathways
Analysis tool (IPA, http://www.ingenuity.com), based on
extensive records maintained in the Ingenuity Pathways
Knowledge Base (IPKB).
Real time quantitative RT-PCR
High-throughput real-time qPCR was performed accord-
ing to the manufacturer’s protocol on the BioMark 48.48
Dynamic Array (Fluidigm®, South San Francisco, CA,
USA) with Taqman Gene Expression Assays (Applied
Biosystems, Foster City, CA, USA), (Table 11). qRT-PCR
was run in triplicates in all samples and TBP and HPRT1
were used as endogenous control genes to normalize tran-
scription levels amongst patients. Results were analyzed
with qBaseplus software (Biogazelle, Zwijnaarde, Belgium).
Immunohistochemistry and immunofluorescence
Cryosections (7 μm thick) were labelled without prior fixa-
tion using primary antibodies diluted in PBS 0.1%
Tween-20. Immunofluorescence was visualised with
species-specific secondary antibodies directly linked to
Alexa-fluorophores (Molecular Probes, Eugene, OR,
USA). Nuclei were visualised using DAPI (Molecular
Probes, Eugene, OR, USA) diluted in PBS 0.1% Tween-
20. Immunohistochemistry was performed using Novo-
Link peroxidase detection kit according to manufacturer’s
instructions (Novo-Link peroxidase detection kit, Leica
Microsystems, Wetzlar, Germany). We used mouse mono-
clonal antibody against MHC Class I (Dako, Glostrup
Denmark, Cat. M0736, 1:1000) and rabbit polyclonal anti-
body against active caspase-3 (Pharmingen, San Diego, CA,
USA, Cat. 559565, 1:400). Non-specific labelling was
assessed using sections incubated without primary anti-
bodies. Immunofluorescence was visualised under a con-
ventional epifluorescence microscope (Leica DM5000B).
Table 11 qRT-PCR primers
Gene name Gene symbol Taqman gene expression assays
TATA box binding protein TBP Hs99999910_m1
Hypoxanthine phosphoribosyltransferase 1 HPRT1 Hs02800695_m1
Actin, beta ACTB Hs01060665_g1
Desmin DES Hs00157258_m1
3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial) HMGCS2 Hs00985427_m1
Serine hydroxymethyltransferase 2 (mitochondrial) SHMT2 Hs00193658_m1
Argininosuccinate synthase 1 ASS1 Hs01597989_g1
Tumor protein p53 inducible protein 3 TP53I3 Hs00153280_m1
Complement component 3 C3 Hs00163811_m1
Tumor protein p53 TP53 Hs01034249_m1
Hemoglobin, beta HBB Hs00758889_s1
G0/G1switch 2 G0S2 Hs00274783_s1
Collagen, type XIX, alpha1 COL19A1 Hs00156940_m1
Protein tyrosine phosphatase, receptor type, F PTPRF Hs00892965_m1
Peroxisome proliferator-activated receptor gamma PPARG Hs01115513_m1
Fructose-1,6-bisphosphatase 2 FBP2 Hs00427791_m1
Cytochrome b MT-CYB Hs02596867_s1
Lactate dehydrogenase A LDHA Hs00855332_g1
aarF domain containing kinase 3 ADCK3 Hs00220382_m1
Troponin T type 2 (cardiac) TNNT2 Hs00165960_m1
ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 ATP2A1 Hs01092295_m1
Dihydropyrimidinase-like 4 DPYSL4 Hs01067761_m1
Fibroblast growth factor 21 FGF21 Hs00173927_m1
Tribbles homolog 3 (Drosophila) TRIB3 Hs01082394_m1
Growth differentiation factor 15 GDF15 Hs00171132_m1
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 PFKFB3 Hs00998700_m1
Succinate-CoA ligase, ADP-forming, beta subunit SUCLA2 Hs00605838_g1
Thymidine kinase 2, mitochondrial TK2 Hs00177950_m1
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Microsystems, Wetzlar, Germany) and were quantified with
ImageJ software (http://rsbweb.nih.gov/ij/).TUNEL Assay
The TUNEL assay was employed to examine apoptosis via
DNA fragmentation using the ApopTag Plus Peroxidase
In Situ Apoptosis Detection Kit (Millipore Corporation,
Billerica, MA, USA, Cat. S7101) according to manufac-
turer’s instructions.GDF-15 serum levels
We analysed serum samples collected from patients
and controls of paediatric age. We measured GDF-15 con-
centration in duplicate samples using the human GDF-15
Quantikine ELISA kit (R&D Biosystems, Minneapolis, US)
according to Manufacturer’s instructions. The values fromeach assay were extrapolated from a standard four param-
eter logistic (4-PL) curve fit. Since serum samples were di-
luted, the concentration read from the standard curve was
multiplied by 4 to obtain the final pg/mL concentration.Statistical analysis
Average values are expressed as mean ± standard error
(MEAN± SE). Significance was tested by Student unpaired
t-test and P-value <0.05 was considered as significant (NS,
non-significant, *P < 0.05, **P < 0.01 and ***P < 0.001).Availability of supporting data
Gene expression data has been deposited at the National
Centre for Biotechnology Information Gene Expression
Omnibus (GEO) database as GEO Series accession num-
ber GSE43698.
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